- Home
- Research
- Mental Health
- Authorization of storefront recreational cannabis retailers and cannabis-related healthcare encounters: A local-level spatial difference-in-differences analysis in California, United States.
Local dispensary policies linked to healthcare visit patterns
Authorization of storefront recreational cannabis retailers and cannabis-related healthcare encounters: A local-level spatial difference-in-differences analysis in California, United States.
AI Summary
This study examined the relationship between local government decisions to authorize recreational cannabis retailers and subsequent cannabis-related healthcare visits across California communities. While California legalized recreational cannabis statewide, individual cities and counties can choose whether to allow storefront dispensaries in their jurisdictions. Using a spatial difference-in-differences analysis, researchers compared healthcare encounter rates in communities that authorized retailers versus those that did not, controlling for geographic proximity and spillover effects.
The research provides critical insights into how cannabis retail policy impacts public health outcomes at the local level. By analyzing the timing of when different municipalities authorized retailers and tracking healthcare data, the study reveals whether increased retail access correlates with changes in cannabis-related emergency department visits, hospitalizations, or other medical encounters. This evidence is particularly valuable for local policymakers weighing whether to authorize dispensaries in their communities, as well as for understanding the real-world health impacts of expanding legal cannabis access beyond just statewide legalization to actual retail availability.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More Mental Health research papers you might find interesting.
Review describes AHC and reports cannabidiol as an additional treatment option
Review finds school prevention often covers cannabis, but evidence gaps remain
Antipsychotics eased symptoms, but relapse-prevention evidence remains thin
Explore More Research
Stay informed about the latest cannabis science.